UK trial reports 4-year event-free survival of 63% and overall survival of 68% in relapsed Wilms tumour patients
High-dose chemo plus stem cell rescue offers hope for relapsed Wilms tumour
This clinical trial report evaluates outcomes for 78 children with relapsed or refractory Wilms tumour treated in the United Kingdom.
A UK trial found that a risk-stratified protocol with high-dose melphalan and stem cell rescue helped some children with relapsed Wilms tumo…
Network meta-analysis of pharmacological interventions for hand-foot syndrome in cancer patients undergoing chemotherapy
Simple cream could stop painful hand and foot syndrome side effects
This network meta-analysis evaluated pharmacological interventions for hand-foot syndrome prevention in cancer patients undergoing chemother…
New research suggests a common pain cream could protect cancer patients from painful hand and foot syndrome during treatment.
Undifferentiated Pleomorphic Sarcoma Recurrence Observed two months Postoperatively in Case Report of Gastric Mass
Cancer returns quickly after surgery and chemo for a 71-year-old woman
This case report and literature review describes a 71-year-old female with undifferentiated pleomorphic sarcoma treated with R0 resection, s…
A 71-year-old woman with rare stomach tumors had surgery and chemo, but the cancer came back just two months later.
High-dose pegylated liposomal doxorubicin shows comparable survival to conventional doxorubicin in DLBCL with reduced toxicity
A Gentler Chemo Version Holds Its Own in Lymphoma
A retrospective cohort of 512 DLBCL patients found comparable 2-year PFS (74.3% vs.
A gentler chemo drug wrapped in fat bubbles matched standard treatment for lymphoma survival while sharply cutting serious side effects like…
AN+AD combination therapy yields high response rates in nonbulky classical Hodgkin lymphoma patients
A New Treatment Path for Hodgkin Lymphoma Shows Stunning Success
This Phase 2 study evaluated AN+AD (brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine) in 154 patients with nonbulky classical Ho…
A promising new treatment approach for early-stage Hodgkin lymphoma is delivering remarkable results with less intensive chemotherapy.
Durvalumab plus chemotherapy shows 35% response in phase II trial for metastatic pulmonary sarcomatoid carcinoma
Small study tests drug combination for rare, aggressive lung cancer
A phase II single-arm trial in 20 patients with recurrent/metastatic pulmonary sarcomatoid carcinoma evaluated durvalumab plus doxorubicin/i…
A rare lung cancer drug combo shrank tumors in 35% of patients, offering hope for those with this aggressive disease despite common side eff…